Ethosuximide
Who holds supplier records for Ethosuximide? 1 organisation holds a current record for Ethosuximide: an active US FDA Type II Drug Master File or a CEP. 1 of them holds a valid EU Certificate of Suitability. Recorded organisation countries for current records: Netherlands (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Ethosuximide: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/ethosuximide
Reading the evidence
- One current record
One organisation holds a current DMF or CEP. A record shows a regulatory filing, not current commercial availability or a qualified source for your product.
- 1 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (1)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Ethosuximide. Country is the organisation's recorded country, not necessarily the manufacturing site.
- KATWIJK CHEMIE BVNetherlandsCEP Company GMP cert on recordActive DMF 7937 · latest filing Feb 1989
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (1)
Certificates of Suitability on the EDQM register for Ethosuximide, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| KATWIJK CHEMIE BV Katwijk ZH | NL | R1-CEP 2009-022 - Rev 04 Ethosuximide | May 2018 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Overview
Ethosuximide is an anticonvulsant medication primarily used to treat absence seizures. It operates by stabilizing neuronal activity in the brain, helping to prevent the occurrence of seizures.
Chemical identity
- IUPAC name
- 3-ethyl-3-methylpyrrolidine-2,5-dione
- Canonical SMILES
- CCC1(CC(=O)NC1=O)C
- InChIKey
- HAPOVYFOVVWLRS-UHFFFAOYSA-N
- Synonyms
- Zarontin API, ci-366, cn-10,395, cn-10395, ethosuximidum, nsc-64013, pm-671, pyknolepsinum, zarontin
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Anti-epileptic Agent
- Physiologic effect
- Decreased Central Nervous System Disorganized Electrical Activity
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Ethosuximide?
1 organisation holds an active US FDA Type II Drug Master File or a CEP for Ethosuximide: KATWIJK CHEMIE BV (Netherlands). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Ethosuximide Drug Master Files are active?
KATWIJK CHEMIE BV (DMF 7937). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does Ethosuximide have a European Certificate of Suitability?
Yes. 1 organisation holds a valid CEP for Ethosuximide on the EDQM register, including KATWIJK CHEMIE BV Katwijk ZH (NL). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
How do I qualify a Ethosuximide supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Ethosuximide?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.